Skip to Content

What are the new drugs for the treatment of hepatitis C?

Medically reviewed by Drugs.com. Last updated on Sep 16, 2019.

Official Answer

by Drugs.com

The newest drugs for the treatment of hepatitis C include Mavyret, Vosevi, and Epclusa.

Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).

  • Vosevi and Epclusa are only indicated for use in the treatment of adult patients, while Mavyret can also be used to treat pediatric patients 12 years and older.
  • Epclusa is also approved for the treatment of HCV patients with decompensated cirrhosis (for use in combination with ribavirin).
  • Vosevi is used as a re-treatment option in patients who have been previously treated with an NS5A inhibitor-containing regimen (GT1-6), or a regimen containing sofosbuvir without an NS5A inhibitor (GT1a or GT3).

Latest FDA Approvals for Hepatitis C

Drug Type Dosage Form Company Hepatitis C Indications Patient Population
Mavyret
(glecaprevir and pibrentasvir)

FDA Approved 2017
glecaprevir
NS3/4A protease inhibitor
pibrentasvir
NS5A inhibitor
tablets AbbVie Inc. genotypes 1,2,3,4,5,6 adults and children 12 years and older
Vosevi
(sofosbuvir, velpatasvir, and voxilaprevir)

FDA Approved 2017
sofosbuvir
nucleotide analog NS5B polymerase inhibitor
velpatasvir
NS5A inhibitor
voxilaprevir
NS3/4A protease inhibitor
tablets Gilead Sciences, Inc. genotypes 1,2,3,4,5,6 adults
Epclusa
(sofosbuvir and velpatasvir)

FDA Approved 2016
sofosbuvir
nucleotide analog NS5B polymerase inhibitor
velpatasvir
NS5A inhibitor
tablets Gilead Sciences, Inc. genotypes 1,2,3,4,5,6 adults
Zepatier
(elbasvir and grazoprevir)

FDA Approved 2016
elbasvir
NS5A inhibitor
grazoprevir
NS3/4A protease inhibitor
tablets Merck genotypes 1 or 4 adults
Viekira Pak
(ombitasvir, paritaprevir, and ritonavir tablets / dasabuvir tablets

FDA Approved 2014
ombitasvir
NS5A inhibitor
paritaprevir
NS3/4A protease inhibitor
ritonavir
CYP3A inhibitor
dasabuvir
non-nucleoside NS5B palm polymerase inhibitor
tablets (co-packaged) AbbVie Inc. genotypes 1a or 1b adults
Harvoni
(ledipasvir and sofosbuvir)

FDA Approved 2014
ledipasvir
NS5A inhibitor
sofosbuvir
nucleotide analog NS5B polymerase inhibitor
tablets and oral pellets Gilead Sciences, Inc. genotypes 1, 4, 5 or 6 adults and children 3 years and older
Sovaldi
(sofosbuvir)

FDA Approved 2013
sofosbuvir
nucleotide analog NS5B polymerase inhibitor
tablets and oral pellets Gilead Sciences, Inc. genotypes 1, 2, 3 or 4 adults (GT1-4) and children 3 years and older (GT2-3)
Discontinued
Viekira XR
(dasabuvir, ombitasvir, paritaprevir, and ritonavir)

FDA Approved 2016
(discontinued)
dasabuvir
non-nucleoside NS5B palm polymerase inhibitor
ombitasvir
NS5A inhibitor
paritaprevir
NS3/4A protease inhibitor
ritonavir
CYP3A inhibitor
extended
release
tablets
AbbVie Inc. genotypes
1a or 1b
adults
Daklinza
(daclatasvir)

FDA Approved 2015
(discontinued)

daclatasvir
NS5A inhibitor
tablets BMS genotypes 1 or 3 adults
Technivie
(ombitasvir, paritaprevir,
and ritonavir)

FDA Approved 2015
(discontinued)

ombitasvir
NS5A inhibitor
paritaprevir
NS3/4A protease inhibitor
ritonavir
CYP3A inhibitor
tablets AbbVie Inc. genotype 4 adults
Olysio
(simeprevir)

FDA Approved 2013
(discontinued)

simeprevir
NS3/4A protease inhibitor
capsules Janssen Pharmaceuticals, Inc. genotypes 1 or 4 adults
Incivek
(telaprevir)

FDA Approved 2011
(discontinued)
telaprevir
NS3/4A protease inhibitor
tablets Vertex Pharmaceuticals Inc. genotype 1 adults
Victrelis
(boceprevir)

FDA Approved 2011
(discontinued)

boceprevir
NS3/4A protease inhibitor
capsules Merck genotype 1 adults

For more information, see Oral Hepatitis C Treatments: The Evolving Landscape

Related Medical Questions

Related Support Groups